REGISTER
MedJ Interview: Tony Mok on Lorlatinib's 7-Year PFS in ALK+ NSCLC
At ASCO 2026, Prof. Tony Mok discusses the 7-year follow-up data from the CROWN study, the implications of lorlatinib's median PFS exceeding 7 years for first-line ALK-positive NSCLC treatment, and the shifts in treatment philosophy this milestone brings — including key research priorities for the next five years.

Tony Mok, MD, Chairman, Department of Clinical Oncology, The Chinese University of Hong Kong; Fellow, Hong Kong Academy of Sciences; Fellow, Royal College of Physicians (London)

With lorlatinib achieving a median progression-free survival (PFS) exceeding 7 years in the CROWN study, does the treatment paradigm for ALK-positive metastatic non-small cell lung cancer (NSCLC) now call for a fundamental rethinking — from an oncologic urgency model to a chronic disease management framework? At ASCO 2026, Prof. Mok presents the 7-year follow-up data from the CROWN Phase III trial and evaluates what the durability of lorlatinib's efficacy signals in the first-line setting. He contextualizes these findings against two years of evolving evidence across the ALK-inhibitor landscape, examining how the latest data may reshape treatment selection for ALK-positive NSCLC and what benchmarks remain unmet. Prof. Mok further reflects on the broader philosophical implications of long-term disease control in this population — including shifts in how clinicians approach sequencing, toxicity management, and patient communication — and outlines the most urgent open questions that should define the field's research agenda over the next five years.

0
0
Loading